Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer

Figure 1

Decision model for early stage breast cancer. a RS-assay versus Canadian clinical practice±. b Schematic representation of the Markov model structure “E”*‡. c Schematic representation of the Markov model structure “C”†‡.± The risk classification criteria in the Canadian clinical practice arm was based on the Canadian clinical practice guidelines for adjuvant systemic therapy for women with node-negative breast cancer [4] * Patients entering Markov model “E” start the model and remain in the remission state unless they relapse (LR, DR or Dead). † Patients entering Markov model “C” start the model in the remission state with no CSAE. Within the first cycle patients may develop CSAE. These patients will make a transition to the remission state with CSAE. During the first cycle, patients also may transition to DR, LR and Dead states. After the first cycle, patients may remain in the two remission states unless they relapse in to LR DR or Dead. ‡ In both Markov models, patients who developed LR, remain in the LR state or make transition to DR or Dead states. Patients who developed DR remain in the DR state or make transition to the Dead state. The cycle length was 1 month. LR, loco-regional recurrence; DR, distant recurrence; CSAE, chemotherapy-related serious adverse effects.

Back to article page